Johnson & Johnson is normally a good buy for its dividend and the stability it offers. Over the past five years, however, the ...

The Food and Drug Administration approved Johnson & Johnson's nasal spray ... first-ever stand-alone therapy for treatment-resistant depression, which is when trying at least two standard ...

approved Johnson & Johnson’s nasal spray, Spravato (esketamine), to treat major depressive disorder. Oral antidepressants are the most common treatment for depression, but they don’t work for ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and similar ...

Johnson & Johnson, a leader in immunology, has developed ARGES, a new AI-powered tool that could transform endoscopic ...

For people with AD, Johnson & Johnson's research offers hope ... “Many patients with AD have higher rates of depression, anxiety, stress and suicide,” she says. Existing treatments for AD ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral antidepressants.

Johnson & Johnson (NYSE ... Its key product, Caplyta, is an approved treatment for schizophrenia and depression related to bipolar I or II disorder. It may also soon obtain approval for major ...